@article{4fa5041ea5df4e7b81bbbba5a71f543c,
title = "COVID-19 will change MS care forever – No",
author = "Paolo Preziosa and Rocca, {Maria A.} and Massimo Filippi",
note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr P.P. received speaker honoraria from Biogen Idec, Novartis, Merck Serono, and ExceMED. Dr M.A.R. received speaker honoraria from Biogen Idec, Novartis, Genzyme, Teva, Merck Serono, Roche, Celgene, and Bayer, and receives research support from the Italian Ministry of Health, MS Society of Canada, and Fondazione Italiana Sclerosi Multipla. Prof. M.F. is Editor-in-Chief of the Journal of Neurology ; received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = sep,
day = "1",
doi = "10.1177/1352458520929971",
language = "English",
volume = "26",
pages = "1149--1151",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "10",
}